Form 4: Clover Health CEO Andrew Toy Reports Stock Transactions
Statement of Changes in Beneficial Ownership
Clover Health Investments, Corp. CEO Andrew Toy reported transactions involving Class A Common Stock, including the vesting of restricted stock units and the withholding of shares for tax obligations.
Summary
- Andrew Toy, CEO of Clover Health Investments, Corp., reported transactions on April 1, 2026.
- These transactions involved Class A Common Stock.
- 956,307 shares were acquired under a restricted stock unit (RSU) award, with vesting scheduled through April 1, 2030.
- 309,558 shares were withheld to cover tax obligations upon the vesting of a portion of previously granted RSUs.
- Following these transactions, Toy beneficially owns 10,379,328 shares directly and 10,069,770 shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine executive stock transactions and vesting schedules rather than significant new financial information or strategic shifts.
Positives
- Vesting of restricted stock units indicates continued service and potential future value realization for the CEO.
- The company is managing tax obligations related to stock awards efficiently through share withholding.
Negatives
- Withholding of shares for tax obligations represents a reduction in the net shares received by the reporting person.
Risks
- The vesting schedule for RSUs is subject to continued service, meaning any departure before vesting dates would result in forfeiture of unvested shares.
- The value of the withheld shares is subject to market fluctuations until they are sold.
Future Outlook
The vesting schedule for the restricted stock units extends through April 1, 2030, indicating a long-term incentive plan for the CEO, contingent on continued service.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions. The details of RSU vesting and tax withholding are common practices in executive compensation within the healthcare technology sector.
Stakeholder Impact
- Shareholders: The transactions do not directly impact the number of outstanding shares but reflect executive compensation and potential future selling pressure if shares are sold.
- Employees: The vesting of RSUs for the CEO aligns executive incentives with company performance and long-term growth.
- Management: The transactions confirm the CEO's continued commitment and equity stake in the company.
Next Steps
- Continued vesting of restricted stock units through April 1, 2030, subject to continued service.
- Potential future sales of vested shares by the reporting person.
Key Dates
| Date | Description |
|---|---|
| 01/01/2023 | Date of original grant for certain restricted stock units. |
| 01/04/2023 | Date of a prior Form 4 filing related to RSU grants. |
| 04/01/2026 | Earliest transaction date reported; date of RSU vesting and tax withholding. |
| 04/01/2030 | Full vesting date for the RSU award reported under footnote (1). |
| 01/01/2027 | Final vesting date for the remaining RSUs mentioned in footnote (2). |
| 04/03/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Clover Health, CLOV, Andrew Toy, Beneficial Ownership, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.